Comparison of the collagen haemostat Sangustop® versus a carrier-bound fibrin sealant during liver resection; ESSCALIVER-Study
Christian Moench, Wolf O Bechstein, Valentin Hermanutz, Godehard Hoexter, Hanns-Peter Knaebel, Christian Moench, Wolf O Bechstein, Valentin Hermanutz, Godehard Hoexter, Hanns-Peter Knaebel
Abstract
Background: Haemostasis in liver surgery remains a challenge despite improved resection techniques. Oozing from blood vessels too small to be ligated necessitate a treatment with haemostats in order to prevent complications attributed to bleeding. There is good evidence from randomised trials for the efficacy of fibrin sealants, on their own or in combination with a carrier material. A new haemostatic device is Sangustop®. It is a collagen based material without any coagulation factors. Pre-clinical data for Sangustop® showed superior haemostatic effect. This present study aims to show that in the clinical situation Sangustop® is not inferior to a carrier-bound fibrin sealant (Tachosil®) as a haemostatic treatment in hepatic resection.
Methods/design: This is a multi-centre, patient-blinded, intra-operatively randomised controlled trial. A total of 126 patients planned for an elective liver resection will be enrolled in eight surgical centres. The primary objective of this study is to show the non-inferiority of Sangustop® versus a carrier-bound fibrin sealant (Tachosil®) in achieving haemostasis after hepatic resection. The surgical intervention is standardised with regard to devices and techniques used for resection and primary haemostasis. Patients will be followed-up for three months for complications and adverse events.
Discussion: This randomised controlled trial (ESSCALIVER) aims to compare the new collagen haemostat Sangustop® with a carrier-bound fibrin sealant which can be seen as a "gold standard" in hepatic and other visceral organ surgery. If non-inferiority is shown other criteria than the haemostatic efficacy (e.g. costs, adverse events rate) may be considered for the choice of the most appropriate treatment.
Trial registration: NCT00918619.
Figures
References
- Bechstein WO, Strey C. [Local and systemic hemostasis in surgery] Chirurg. 2007;78:95–100. doi: 10.1007/s00104-006-1289-x.
- Schwartz M, Madariaga J, Hirose R, Shaver TR, Sher L, Chari R, Colonna JO, Heaton N, Mirza D, Adams R, Rees M, Lloyd D. Comparison of a new fibrin sealant with standard topical hemostatic agents. Arch Surg. 2004;139:1148–1154. doi: 10.1001/archsurg.139.11.1148.
- Chapman WC, Sherman R, Boyce S. A novel collagen-based composite offers effective hemostasis for multiple surgical indications: Results of a randomized controlled trial. Surgery. 2001;129:445–450. doi: 10.1067/msy.2001.112365.
- Frilling A, Stavrou GA, Mischinger HJ, de HB, Rokkjaer M, Klempnauer J, Thörne A, Gloor B, Beckebaum S, Ghaffar MF, Broelsch CE. Effectiveness of a new carrier-bound fibrin sealant versus argon beamer as haemostatic agent during liver resection: a randomised prospective trial. Langenbecks Arch Surg. 2005;390(2):114–120. doi: 10.1007/s00423-005-0543-x.
- Siemer S, Lahme S, Altziebler S, Machtens S, Strohmaier W, Wechsel HW, Goebell P, Schmeller N, Oberneder R, Stolzenburg JU, Becker H, Lüftenegger W, Tetens V, Van Poppel H. Efficacy and safety of TachoSil as haemostatic treatment versus standard suturing in kidney tumour resection: a randomised prospective study. Europ Urol. 2007;52:1156–1163. doi: 10.1016/j.eururo.2007.04.027.
- Takacs I, Wegmann J, Ferencz S, Ferencz A, Horvath S, Weber G. Comparing different haemostatic devices to stop severe liver bleedings - An animal study. Brit J Surg. 2008;95(S6):54. (Abstract)
- Newcombe RG. Interval estimation for the difference between independent proportions: comparison of eleven methods. Statist Med. 1988;17:873–890. doi: 10.1002/(SICI)1097-0258(19980430)17:8<873::AID-SIM779>;2-I.
- Kraus TW, Mehrabi A, Schemmer P, Kashfi A, Berberat P, Buchler MW. Scientific evidence for application of topical hemostats, tissue glues, and sealants in hepatobiliary surgery. J Am Coll Surg. 2005;200:418–427. doi: 10.1016/j.jamcollsurg.2004.09.047.
- Kruger J. [Hemostasis in neurosurgical operations. A comparative study between collagen fleece (Lyostypt) and a gelatine sponge (Marbagelan)] Zentralbl Neurochir. 1992;53:33–36.
- Broelsch C, Frühaus NR, de Hemptinne B, Klempnauer J, Mischinger HJ, Büchler MW. et al.Tachosil as haemostatic treatment in hepativ surgery. HPB. 2005;7(Suppl 1):19–31.
- Piaggio G, Elbourne DR, Altman DG, Pocock SJ, SJ Evans. for the CONSORT Group. Reporting of Noninferiority and Equivalence Randomized Trials: An Extension of the CONSORT Statement. JAMA. 2006;295:1152–1160. doi: 10.1001/jama.295.10.1152.
Source: PubMed